Switzerland
  • Switzerland
  • USA
  • confinis ag, Hauptstrasse 16, CH-3186 Düdingen, Switzerland
  • info.ch@confinis.com
  • +41 26 494 8 494
  • confinis corp., 4445 Willard Ave, Suite 600, Chevy Chase, MD 20815, USA
  • info.usa@confinis.com
  • +1 240 252 0891
confinis
confinis
  • Home
  • About
  • Services
    • Combination Products
    • In-Vitro Diagnostics
    • Product Development
    • QM, Auditing & Training
    • Regulatory Affairs
  • Blog
  • Join
    • Careers
    • Independent professional
  • Contact
    • Offices
    • Newsletter
    • Disclaimer
    • Cookie Policy
   
  • Join our Startup Workshop 2022!
    October 20, 2022
  • UK Responsible Person Services
    December 20, 2021
  • Join our second Start-up Workshop 2021!
    October 25, 2021
  • Join our Startup Workshop 2021!
    April 24, 2021
  • … and Report your Post-Market Clinical Follow-up Evaluation!
    April 23, 2021
  • How to plan your post-market clinical follow up…
    March 10, 2021
  • How does the notified body assess your clinical evaluation?
    February 18, 2021
  • How to perform a clinical evaluation for Medical Device Software
    January 28, 2021
  • How to ensure sufficient clinical evidence for legacy devices
    January 15, 2021
  • How to claim an equivalence in the clinical evaluation under the MDR
    December 21, 2020
The confinis Blog

Welcome to the confinis blog. This is the place where we are writing about news, events and helpful information. Enjoy.

Archives
Categories
  • Conferences
  • confinis
  • Regulations
  • Workshops
Tags
#2017/745 #CHREP #FDA #machinelearning 2018 BLA clinicalevaluation combination products confinis digitalhealth EMC howto IEC60601 IEC80601 InstA ISO13485 IVD ivdr MDCG mdr mdr article 117 MedDO medicaldevices medicalsoftware medizinprodukte Medizinprodukteverordnung MepV mhra motivation MRA NIS OBDS peter studer PMS post-market-clinical-follow-up post-market-surveillance presentation qms regulations samd startup swiss-medtech switzerland TOPRA ukrp

Combination Products Services

  • MDR Article 117
  • Combination Products
  • Design Control
  • Risk Management
  • Usability Engineering
  • Clinical Evaluation
  • 21 CFR Part 4

In-Vitro Diagnostics

  • New IVDR
  • Classification and Regulatory Strategy
  • CE marking, FDA and global product registrations
  • Performance Evaluation
  • Software

Product Development Services

  • Digital Health
  • Design Control
  • Risk Management
  • Usability Engineering
  • Clinical Evaluation
  • Regulatory Due Diligence
  • Combination Products
  • DHF Remediation
  • Software Validation
  • Mobile Medical Apps
  • Production & Process Optimization
  • Packaging

QM, Auditing & Training Services

  • eQMS
  • Quality Management System
  • Design Control
  • Training
  • Auditing
  • Validation / Qualification
  • FDA Inspections
  • Postmarket Surveillance

Regulatory Affairs & Market Authorization

  • Digital Health
  • Regulatory Affairs Strategy
  • Market Authorization in Europe
  • Market Authorization in the USA
  • Market Authorization in other Markets
  • EC Representative
  • US Agent
RAPS - Enterprise Member Logo
© 2023 confinis ag. All rights reserved. Disclaimer & Cookie Policy. Website: SENF Digital Graphics: zwo13